Cat. No. | Product name | CAS No. |
DCC2831 |
Jnj-10311795
Novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase |
518062-14-1 |
DCC2832 |
Jnj-17029259
Vascular endothelial growth factor receptor-2 (VEGF-2) kinase inhibitor |
314267-57-7 |
DCC2833 |
Jnj-17148066
Estrogen receptor ESR1 agonist |
554431-74-2 |
DCC2834 |
Jnj-1930942
Novel Positive Allosteric Modulator of the α7 Nicotinic Acetylcholine Receptor |
929562-28-7 |
DCC2835 |
Jnj-20788560
Selective delta opioid receptor agonist as a potent and efficacious antihyperalgesic agent |
825649-28-3 |
DCC2836 |
Jnj-26076713
Novel EthR inhibitor, boosting antituberculous activity of ethionamide |
669076-03-3 |
DCC2837 |
Jnj-28330835
Selective androgen receptor modulator with minimal prostate hypertrophic activity stimulating sexual behavior in female rats |
888072-47-7 |
DCC2838 |
Jnj-28583867
Histamine H3 receptor antagonist and serotonin reuptake inhibitor |
892407-39-5 |
DCC2839 |
Jnj-40068782
Novel potent, selective, and systemically active positive allosteric modulator (PAM) of mGlu2-receptors |
950196-50-6 |
DCC2840 |
Jnj-40255293
Novel Adenosine A 2A /A 1 Antagonist With Efficacy In Preclinical Models of Parkinson's Disease |
1147271-25-7 |
DCC2841 |
Jnj-40264796
Negative control for JNJ-40068782 |
|
DCC2842 |
JNJ-40355003
Featured
JNJ-40355003 is a potent and selective atty acid amide hydrolase (FAAH) inhibitor. |
1394894-41-7 |
DCC2843 |
Jnj-40573663
Negaive control for JNJ-42396302 |
|
DCC2844 |
Jnj-40929837
Novel potent, orally active LTA4H inhibitor |
1191044-42-4 |
DCC2845 |
Jnj-42396302
Novel inhibitor of PDE10A |
1298030-18-8 |
DCC2846 |
Jnj-42491293
Novel ago-PAM for the metabotropic glutamate receptor subtype 2 (mGluR2) |
1376334-37-0 |
DCC2847 |
Jnj-49153390
Novel inhibitor of respiratory syncytial virus (RSV), binding the RSV F glycoprotein and inhibiting membrane fusion |
|
DCC2848 |
Jnj-53721590
Negative control for JNJ-54119936 |
|
DCC2849 |
Jnj-61432059
Novel TARP γ-8 Selective AMPAR Negative Modulator |
2035814-50-5 |
DCC2850 |
Jnj-dgat1-a
Selective DGAT1 inhibitor |
1092067-85-0 |
DCC2851 |
Jnj-dgat2-b
Selective DGAT2 inhibitor |
|
DCC2852 |
Jns 1-40
Novel cysteine-reactive covalent ligand, selectively targeting C377 of PPP2R1A to impair breast cancer signaling, proliferation, and in vivo tumor growth |
|
DCC2853 |
Jp1201
Novel SMAC mimetic, sensitizing non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner |
|
DCC2854 |
Jp4-039
Non-toxic radioprotector GS-nitroxide, improving hematopoiesis in long-term bone marrow cultures (LTBMCs) |
1205492-16-5 |
DCC2855 |
Jr-220
Non-toxic anti-relapse agent, acamprosate |
6933-71-7 |
DCC2856 |
Jra-003
Novel selective inhibitor of nuclear translocation of IKKα as the most potent synthetic gibberellin against cancer-derived cell lines, displaying no cytotoxicity in cells derived from noncancerous sources (HEK 293T, HS 578BST, HS 888Lu, HS 895Sk, HUVEC) |
|
DCC2857 |
Jrc-ii-191
Novel inhibitor of CD4-gp120 binding, blocking the binding of the HIV-1 envelope glycoprotein gp120 to the CD4 receptor |
|
DCC2858 |
Js399-19
Novel specific inhibitor of Fusarium myosin I; Fungicide |
39491-78-6 |
DCC2859 |
Jsf-2019
Novel antitubercular agent, inhibiting InhA and FAS-II pathway |
|
DCC2860 |
Jsf-2513
Novel potent antitubercular agent, inhibiting InhA and FAS-II pathway |
|
DCC2861 |
Jsi287
Novel ERK inhibitor, alleviating IMQ-induced mice skin lesions through ERK/IL-17 signaling pathway |
|
DCC2862 |
Jte-151
Novel RORγ |
1608139-41-8 |
DCC2863 |
Jte-607
Cytokine release inhibitor, inhibiting production of IL-1ß, IL-8, IL-6, IL-10 and TNFalpha |
188791-71-1 |
DCC2864 |
Jtk-853
Novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase |
954389-09-4 |
DCC2865 |
Jts-653
Novel orally active and selective transient receptor potential vanilloid 1 (TRPV1) antagonist |
942614-99-5 |
DCC2866 |
Jtt-552
Novel inhibitor of urate transporter 1 (URAT1) |
888730-46-9 |
DCC2867 |
jtv-506
Novel K(ATP) channel opener |
170148-29-5 |
DCC2868 |
Jtv-803 Mesylate
Specific inhibitor of factor Xa |
247131-79-9 |
DCC2869 |
Julolidine Phenoxazone Azide
Novel live-cell peobe of voltage-dependent structural changes of voltage-gated Kv2.1 channels |
|
DCC2870 |
jwb1-84-1 Trihydrochloride
Novel neuroprotective agent, improving cognitive performances in a transgenic mouse model of AD |
491878-69-4 |
DCC2871 |
Jwg-115
Novel BET selective inhibitor, targeting BRD4 |
|
DCC2872 |
Jwh-007
Potent cannabinoid (CB) receptor agonist |
155471-10-6 |
DCC2873 |
Jwu-a021
Novel potent stimulator of glucagon-like peptide-1 (GLP-1) secretion in vitro, also potently stimulating Ca(2+) influx through TRPA1 cation channels, being one of the most potent non-electrophilic TRPA-1 channel agonists |
1403610-23-0 |
DCC2874 |
Jxl069
Novel potent mitochondrial pyruvate carrier (MPC) inhibitor to treat hair loss |
|
DCC2875 |
Jy-1-106
Novel BH3 α-helix mimetic, inducing apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak |
|
DCC2876 |
Jyl-1511
High-affinity partial agonist of the vanilloid receptor |
623166-14-3 |
DCC2877 |
Jyl-273
Potent TRPV1 agonist |
1391826-17-7 |
DCC2878 |
Jyl-79
Potent vanilloid receptor (VR1) agonist |
289902-64-3 |
DCC2879 |
Jy-xhe-053
Selective modulator of GABAA receptors containing the α5 subunit |
612526-36-0 |
DCC2880 |
Jz-4109
Novel β-Glucocerebrosidase modulator, promoting dimerization of β-glucocerebrosidase and revealing an allosteric binding site, stabilizing wild-type and N370S mutant GCase and increases GCase abundance in patient-derived fibroblast cells |
|
DCC2881 |
Jz-5029
Novel irreversible β-Glucocerebrosidase modulator |
|
DCC2882 |
jzad-iv-22
Inhibitor of all three monoamine transporters |
1333245-01-4 |
DCC2883 |
Jzp-430
Potent, highly selective, and irreversible ABHD6 Inhibitor |
1672691-74-5 |
DCC2884 |
K00135
Novel potent and selective inhibitor of PIM kinases |
869650-21-5 |
DCC2885 |
K00518
Novel dual CLK1 and CLK3 inhibitor |
|
DCC2886 |
K103 Hydrochloride
Novel inhibitor of peptidoglycan synthesis targeting the lipid II precursor |
1071544-43-8 |
DCC2887 |
K-14585
Novel antagonist for proteinase-activated receptor 2 (PAR2) |
880546-17-8 |
DCC2888 |
K4610422
Novel norditerpenoid inhibitor of testosterone-5α-reductase |
|
DCC2889 |
K-8008
Novel inhibitor of the interaction of the N-terminally truncated RXR |
2276730-51-7 |
DCC2890 |
K-8012
Novel inhibitor of the interaction of the N-terminally truncated RXR |
1346513-17-4 |
DCC2891 |
Kaempulchraol P
Natural anti-inflammatory agent, inhibiting the NF-κB-mediated transactivation of a luciferase reporter gene, IL-6 production, and COX-2 expression |
|
DCC2892 |
Kaempulchraol Q
Natural anti-inflammatory agent, inhibiting the NF-κB-mediated transactivation of a luciferase reporter gene, IL-6 production, and COX-2 expression |
|
DCC2893 |
Kalb001
Novel mGlu4 ligand |
|
DCC2894 |
Kar425
Novel antimalarial agent, providing protection to malaria-infected mice |
1809050-49-4 |
DCC2895 |
Kasugamycin
Antibiotic, binding within the mRNA channel of the 30S subunit and inhibiting protein synthesis |
6980-18-3 |
DCC2896 |
Kb130015
Novel activator of hERG1 potassium channels, blocking native and recombinant hERG1 channels at high voltages, but activating them at low voltages |
147030-48-6 |
DCC2897 |
Kbh-a42
Novel histone deacetylase inhibitor |
798543-50-7 |
DCC2898 |
Kbjk557
Novel Plk1 PBD inhibitor, showing a remarkable in vitro anticancer effect by inducing Plk1 delocalization, mitotic arrest, and apoptosis in HeLa cells |
|
DCC2899 |
Kb-nb165-09
Selective inhibitor of Protein_kinase_D1>protein kinase D (PKD); Inhibitor of cell adhesion and HIV; Inhibitor of herpes simplex virus type 1 replication |
172832-10-9 |
DCC2900 |
Kbp-088
Novel highly potent dual amylin and calcitonin receptor agonist (DACRA), showing long-lasting improvement of food preference and body weight loss |
|
DCC2901 |
Kb-r7785
Novel ADAM12 and MMP inhibitor, ameliorating cardiac function in a transverse aortic constriction (TAC) model by inhibiting the proteolytic activation of HB-EGF signaling, exerting its antidiabetic effect by ameliorating insulin sensitivity through the in |
168158-16-5 |
DCC2902 |
Kc-11404
LTB4 inhibitor for the treatment of b-cell leukemias and lymphomas, potently inhibiting histamine, platelet activating factor,and 5-lipoxygenase |
148490-22-6 |
DCC2903 |
Kca075
Highly specific transglutaminase 2 (TG2) inhibitor |
|
DCC2904 |
Kca-1490
Dual PDE3/4 inhibitor |
909719-71-7 |
DCC2905 |
Kca2 Positive Modulator 2q
Novel potent and Subtype-Selective Positive Modulator of KCa2 Channels |
|
DCC2906 |
Kcal01
Potent PDZ domain peptide inhibitor that rescues CFTR activity |
|
DCC2907 |
Kdm4c-in-35
Novel selective KDM4C inhibitor |
1841508-48-2 |
DCC2908 |
Kdm4-in-i
Novel KDM4 inhibitor |
23705-85-3 |
DCC2909 |
Kdoam-20
Potent and selective KDM5 inhibitor |
|
DCC2910 |
Kdoam-21
Potent and selective KDM5 inhibitor |
|
DCC2911 |
Kemptide Acetate Salt
Phosphate acceptor peptide substrate for cAMP-dependent protein kinase |
1629902-50-6 |
DCC2912 |
Kf15372
Potent and selective adenosine A1 antagonist with renal protective and diuretic activities |
131080-42-7 |
DCC2913 |
Kfa1982
Novel and potent factor Xa inhibitor |
409358-98-1 |
DCC2914 |
Kgchm07
Novel potent peptide dual agonist of opioid/neurokinin 1 receptor |
|
DCC2915 |
Kh-carb13 Hydrochloride
Novel Pim-1 kinase Inhibitor, dose-dependent decreasing the viability of LS174T and HCT-116 cells |
1353572-78-7 |
DCC2916 |
Khg21834
Inhibitor of Aβ-induced inflammation |
940938-64-7 |
DCC2917 |
Khg26693
Novel anti-inflammatory and antioxidant agent, significantly decreasing blood glucose, triglycerides, and cholesterol and increased insulin |
1497249-95-2 |
DCC2918 |
Ki23057
Novel FGFR2 inhibitor, enhancing the chemosensitivity of drug-resistant gastric cancer cell lines |
516523-31-2 |
DCC2919 |
Kif18a Inhibitor 23
Novel KIF18A inhibitor, causing significant mitotic arrest in vivo, binding at the interface of KIF18A and tubulin |
|
DCC2920 |
Ki-ms2-008
Novel Max-binding modulator, attenuating Myc-driven transcription and stabilizing the Max homodimer |
|
DCC2921 |
kin100
Novel inducer of the ISG54 promoter, causing IRF-3 translocation |
299952-11-7 |
DCC2922 |
Kir1.1-in-a
Novel potent and selective inhibitor of kir1.1 channels |
|
DCC2923 |
Kist301072
Novel ROS1 kinase inhibitor |
|
DCC2924 |
Kist301080
Novel ROS1 kinase inhibitor |
|
DCC2925 |
Kjm429
Novel TRPV1 antagonist |
401907-57-1 |
DCC2926 |
Kj-pyr-10
Novel specific inhibitor of MYC |
|
DCC2927 |
Kkha-761
Potent D3 receptor antagonist with high 5-HT1A receptor affinity |
|
DCC2928 |
Kl-1156
Novel NF-κB inhibitor and lipopolysaccharide (LPS)-induced nitric oxide production inhibitor |
819868-62-7 |
DCC2929 |
Kld-12
Self-assembling peptide, forming a hydrogel matrix to support growth of cells in the presence of an ionic solution, enhancing chondrogenic differentiation of bone marrow stromal cells (BMSCs) |
800379-47-9 |
DCC2930 |
Klebsazolicin
Novel inhibitor of 70S ribosome by obstructing the peptide exit tunnel |
2257496-47-0 |
DCC2931 |
Klk6-in-32
First-in-class inhibitor of Kallikrein-related peptidase 6 (KLK6), promoting the differentiation of OPCs into mature oligodendrocytes in vitro |
|
DCC2932 |
Klk6-in-42
First-in-class inhibitor of Kallikrein-related peptidase 6 (KLK6), promoting the differentiation of OPCs into mature oligodendrocytes in vitro |
|
DCC2933 |
Kl-l9p
Novel antibiotic sensitizer, promoting the rearrangement of the bacterial membrane that enables hydrophobic antibiotics to permeate, strongly sensitizing Gram-negative bacteria to linezolid (Lzd), rifampicin (Rif), or clarithromycin (Clr) |
|
DCC2934 |
Boc-phe-leu-glup(oph)
0 |
|
DCC2935 |
Km05382
CDK9 inhibitor, inhibiting transcription of GAPDH |
882291-64-7 |
DCC2936 |
km10340
Selective S1P3 agonist |
844635-76-3 |
DCC2937 |
Km-5-25
Novel inhibitor of the BfrB-Bfd complex, binding BfrB in the P. aeruginosa cytosol, blocking the BfrB-Bfd interaction and inhibiting iron mobilization from BfrB, resulting in cytosolic iron limitation that is manifested in a pyoverdine hyperproduction phe |
|
DCC2938 |
Km-5-66
Novel inhibitor of the BfrB-Bfd complex, binding BfrB in the P. aeruginosa cytosol, blocking the BfrB-Bfd interaction and inhibiting iron mobilization from BfrB, resulting in cytosolic iron limitation that is manifested in a pyoverdine hyperproduction phe |
|
DCC2939 |
kmi-1764
Novel BACE1 inhibitor with a non-acidic heterocycle at the P1' position |
1469987-42-5 |
DCC2940 |
Kmn-010034
Novel Potent Hematopoietic Prostaglandin D2 Synthase (H-PGDS) Inhibitor |
|
DCC2941 |
Kmn-80
Novel Potent and Selective EP4 Agonist |
1628759-75-0 |
DCC2942 |
kms80013
Novel inhibitor of amyloid- |
930284-65-4 |
DCC2943 |
Kms88009
Novel inhibitor of amyloid-β aggregation, ameliorating the neurodegenerative disorder |
1089681-42-4 |
DCC2944 |
Kmup-3
Novel enhancer of cGMP activity; Aortic smooth muscle relaxant |
421556-16-3 |
DCC2945 |
Kmup-4
Novel enhancer of cGMP activity; Aortic smooth muscle relaxant |
864873-81-4 |
DCC2946 |
Kongensin D
Natural anti-TNBC agent, significantly suppressing the triple-negative breast cancer (TNBC) tumor growth without causing side effects |
|
DCC2947 |
kp1212
Novel non-chain terminating nucleoside analog anti-HIV inhibitor |
114522-16-6 |
DCC2948 |
Kpt-6604
Novel selective, orally bioavailable, PAK4 allosteric modulator against triple negative breast cancer |
|
DCC2949 |
Kpu-300
Novel potent antimicrotubule agent, exhibiting potent cytotoxicity against HT-29 cells by strongly binding to tubulin and inducing microtubule depolymn. |
1620692-60-5 |
DCC2950 |
Kr-12-a4
Potent antimicrobial peptide against gram-positive and gram-negative bacteria and relatively high LPS-neutralization activity |
|
DCC2951 |
Kr-25210
Novel enteroviral replication inhibitor through a non-capsid binding mode with EC 50 values of 2.5, 2.2, and 3.7 μM against hRV B14, A21, and A71, respectively, targeting the replication stages in the virus |
|
DCC2952 |
Kr-31762
Novel KATP channel opener, exerting cardioprotective effects by opening SarcKATP channels in rat models of ischemia/reperfusion-induced heart injury |
|
DCC2953 |
Kras(g12c)-in-1
Novel irreversible inhibitor of KRAS(G12C) |
|
DCC2954 |
Kras4b-in-d14
Novel specific inhibitor of oncogenic KRAS4b signaling, stabilizing the KRAS4b-PDEδ complex and remarkably decreasing tumor size and triggered apoptosis of tumor cells |
924249-06-9 |
DCC2955 |
Kras4b-pdeδ Stabilizer C19
Novel stabilizer of the KRAS4b-PDEδ complex, decreasing the proliferation of colorectal cancer cells, and increasing apoptosis via decreased activation of oncogenic KRAS4b signaling |
1049727-35-6 |
DCC2956 |
Krc-108
Novel potent multi-kinase inhibitor, targeting Ron, Flt3 and TrkA as well as c-Met |
1146944-35-5 |
DCC2957 |
Krc-327
Selective novel inhibitor of c-Met receptor tyrosine kinase with anticancer activity. |
1350612-75-7 |
DCC2958 |
Krm-ii-08
Novel potent, non-toxic, blood-brain barrier crossing, α5-GABA A R preferring ligand, enhancing a chloride-anion efflux that induces mitochondrial membrane depolarization and in response, TP53 upregulation and p53, constitutively phosphorylated at S392, c |
|
DCC2959 |
Krn4884
Potassium channel opener |
152802-84-1 |
DCC2960 |
Krn-8602 Hydrochloride
Topo II inhibitor, exhibiting cytotoxic effects against tumour cells |
131722-57-1 |
DCC2961 |
Krp-109
Novel neutrophil elastase (NE) inhibitor, decreasing expression of TGF-ß Signal Related Genes |
1275996-50-3 |
DCC2962 |
Krp-199
Highly potent and selective antagonist for the AMPA receptors, exhibiting good neuroprotective effects in vivo |
221164-28-9 |
DCC2963 |
Krp-204
Novel highly selective β3-adrenoceptor agonist being developed for the treatment of diabetes and obesity |
220475-76-3 |
DCC2964 |
Ks-133
Novel Potent and Selective VIPR2 Antagonist, Counteracting Cognitive Decline in a Mouse Model of Psychiatric Disorders |
|
DCC2965 |
Ksc-392-150
Novel inhibitor of the permeability transition pore (PTP) |
|
DCC2966 |
kscm-1
Selective ligand of the sigma-1 receptor |
1415247-17-4 |
DCC2967 |
Kscm-11
Ligand of the sigma receptor |
1415247-16-3 |
DCC2968 |
kscm-5
Ligand of the sigma receptor |
1415247-18-5 |
DCC2969 |
Ksk120
Novel inhibitor of transcriptional activity in Chlamydia trachomatis |
1638100-63-6 |
DCC2970 |
Ksl-128114
Novel, highly potent, and metabolically stable peptide inhibitor of syntenin, Inhibiting Glioblastoma |
|
DCC2971 |
Kspa-1
Novel modulator of kinesin spindle protein (KSP)/Eg5, activating KSP-catalyzed ATP hydrolysis in the absence of microtubules yet inhibiting microtubule-stimulated ATP hydrolysis by KSP |
264207-32-1 |
DCC2972 |
Kt-182
Potent and selective inhibitor of ABHD6 |
1402612-62-7 |
DCC2973 |
Kt2-962
TXA2/prostaglandin endoperoxide receptor antagonist |
129648-96-0 |
DCC2974 |
Kta-439
Thyroid hormone receptor β (TRβ) selective agonist |
575503-70-7 |
DCC2975 |
Ku-2285
Hypoxic cell radiosensitizer |
121077-11-0 |
DCC2976 |
Kufal194
Novel selective DYRK1A inhibitor |
|
DCC2977 |
Kunb31
Novel potent and selective inhibitor of Hsp90β |
2220263-80-7 |
DCC2978 |
Kurasoin B
Novel protein farnesyltransferase inhibitor |
193696-42-3 |
DCC2979 |
kv1.5-in-iiii
Potent Kv1.5 inhibitor |
1469902-72-4 |
DCC2980 |
Kv2.1/syntaxin-in-cpd5
Novel neuroprotectant, inhibiting Kv2.1-syntaxin molecular interaction |
|
DCC2981 |
Kva-d-88
Novel Preferable Phosphodiesterase 4B (PDE4B) Inhibitor, Decreasing Cocaine-Mediated Reward Properties in Vivo |
2410550-31-9 |
DCC2982 |
Ky1022
Ras destabilizer, targeting the Wnt/ß-catenin pathway and inhibiting development of metastatic colorectal cancer |
1029721-36-5 |
DCC2983 |
Kya1797
Novel inhibitor of the Wnt/ß-catenin pathway, binding directly to the regulators of G-protein signaling domain of axin, initiating ß-catenin and Ras degradation through enhancement of the ß-catenin destruction complex activating GSK3ß, effectively suppres |
851304-36-4 |
DCC2984 |
Kys05047
Selective T-type Ca(2+) channel blocker with anti-proliferative effects against various cancer cells |
839672-57-0 |
DCC2985 |
L-161240
Potent inhibitor of LpxC and lipid A biosynthesis |
183298-68-2 |
DCC2986 |
L-162782
Nonpeptide agonist of angiotensin AT1 receptor |
169281-92-9 |
DCC2987 |
L17er4
Novel cell-permeable attenuated cationic amphiphilic lytic (ACAL) peptide, efficiently bring immunoglobulin G (IgG) and other functional proteins into cells |
|
DCC2988 |
L2-4048
Novel Migration Inhibitory Factor (MIF) inhibitor, binding at the allosteric and tautomerase sites, blocking MIF's tautomerase CD74 receptor binding, and pro-inflammatory activities |
|
DCC2989 |
L458-bpyne
Novel γ-secretase modulator photoaffinity probe, identifying distinct allosteric binding sites on presenilin that can be exploited to reduce levels of pathogenic Aβ species |
1374647-07-0 |
DCC2990 |
L465046 (α-synuclein Amyloid Aggregation Inhibitor)
Novel inhibitor of α-synuclein amyloid aggregation for the treatment of Parkinson's disease |
675171-18-3 |
DCC2991 |
L524-0366
Novel inhibitor of the TWEAK-Fn14 signaling cascade |
951612-19-4 |
DCC2992 |
L61h46
Novel potent inhibitor of human pancreatic cancer cells |
|
DCC2993 |
L-651392
Potent leukotriene inhibitor |
93211-49-5 |
DCC2994 |
L-658758
Blocker of the activity of human neutrophil elastase (NE), human proteinase-3, human macrophage metalloelastase, mouse macrophage metalloelastase and Pseudomonas aeruginosa elastase |
116507-04-1 |
DCC2995 |
L-663581
Novel partial agonist of the benzodiazepine receptor |
122384-14-9 |
DCC2996 |
L-680833
Potent, orally active monocyclic beta-lactam inhibitor of human polymorphonuclear leukocyte elastase (PMNL-E) |
127063-08-5 |
DCC2997 |
L-682679
HIV protease inhibitor |
126409-24-3 |
DCC2998 |
L-687306
Novel partial agonist of muscarinic M1 receptors |
139346-23-9 |
DCC2999 |
L-696229
HIV-1 non-nucleoside reverse transcriptase inhibitor |
135525-71-2 |
DCC3000 |
L-708906
Inhibitor of Human Immunodeficiency Virus Type 1 (HIV-1) |
251963-74-3 |
DCC3001 |
L-731988
Inhibitor of Strand Transfer, Preventing Integration and Inhibiting HIV-1 Replication in Cells |
251922-77-7 |
DCC3002 |
L-735821
Inhibitor of the KCNQ1 channel |
170228-29-2 |
DCC3003 |
L-739758
Potent glycoprotein IIb/IIIa inhibitor |
168157-33-3 |
DCC3004 |
L-744832
Ras farnesyltransferase inhibitor, inhibiting in p70(s6k) phosphorylation in mammary tumors, inducing tumor regression in transgenic mice by mediating alterations in both cell cycle control and apoptosis |
1177806-11-9 |
DCC3005 |
L-749329
Dual ET(A)/ET(B) endothelin receptor antagonist |
159590-37-1 |
DCC3006 |
L-768673
Class III antiarrhythmic agent, selectively blocking the slowly activating cardiac delayed rectifier potassium current Iks |
177954-68-6 |
DCC3007 |
L-770644
Potent and selective agonist of the human beta3 adrenergic receptor |
173901-95-6 |
DCC3008 |
L-778123
Featured
L-778123 is a dual FPTase and GGPTase-I inhibitor, with IC50s of 2 nM and 98 nM respectively. |
183499-57-2 |
DCC3009 |
L-841411
Novel HIV-1 integrase strand transfer inhibitor (INSTI), stabilizing an integrase-single blunt-ended DNA complex |
|
DCC3010 |
L-858051
Chemically-modified forskolin with greater stability and water solubility than the parent compound |
115116-37-5 |
DCC3011 |
L-870812
Novel inhibitor of HIV-1 and SIV integrase |
410545-90-3 |
DCC3012 |
L-94901
The first organ-selective thyromimetic, lowering plasma low density lipoprotein (LDL) cholesterol and raising plasma high density lipoprotein (HDL) cholesterol levels |
|
DCC3013 |
L-97-1
Adenosine A1 receptor antagonist, reducing allergic responses to house dust mite in an allergic rabbit model of asthma, improving survival and protecting the kidney in a rat model of cecal ligation and puncture induced sepsis, also improving survival and |
770703-20-3 |
DCC3014 |
Lamellarin D
Top1mt inhibitor, targeting mitochondrial DNA |
97614-65-8 |
DCC3015 |
la-mem
Glutamate receptor antagonist and radical scavenging agent |
1552275-56-5 |
DCC3016 |
Lanopepden Mesylate
Novel Peptide Deformylase Inhibitor against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus |
1441390-17-5 |
DCC3017 |
laquinimod Sodium
Novel Modulator of autoimmune demyelination |
248282-07-7 |
DCC3018 |
Largazole
Potent inhibitor of histone deacetylase |
1009815-87-5 |
DCC3019 |
Las191859
Novel, potent and selective CRTh2 antagonist |
|
DCC3020 |
Lasiojasmonate A
Natural fungal phytotoxin, activating the plant jasmonic acid pathway |
|
DCC3021 |
Laspartomycin C
Lipopeptide antibiotic with activity against a range of Gram-positive bacteria including drug-resistant pathogens |
|
DCC3022 |
Lassbio-1135
Novel dual TRPV1 antagonist and TNF-alpha production inhibitor |
852453-71-5 |
DCC3023 |
Lassbio-1359
Novel adenosine receptor agonist, inducing relaxation of corpus cavernosum; Novel selective phosphodiesterase-4 (PDE4) inhibitor associated with anti-TNF-α properties |
1396397-19-5 |
DCC3024 |
Lassbio-1366
Novel Adenosine A2a Receptor Agonist, Attenuating the Progression of Monocrotaline-induced Pulmonary Hypertension |
1396397-03-7 |
DCC3025 |
Lassbio-1524
Novel IKK-β inhibitor, reducing the secretion of TNF-α, IL-1β, IL-6, IL-12, IFN-γ and increased secretion of IL-10, protecting gastrointestinal homeostasis |
|
DCC3026 |
Lassbio-1829 Hydrochloride
Novel orally active IKK2 inhibitor |
1807810-16-7 |
DCC3027 |
Lassbio-1911
Novel Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitor |
|
DCC3028 |
Latonduine A
Natural F508del-CFTR corrector, inhibiting both PARP-3 and -16, regulating the activity of the unfolded protein response activator inositol-requiring enzyme (IRE-1) via modulation of the level of its ribosylation by PARP-16 |
|
DCC3029 |
Latonduine B
Natural F508del-CFTR trafficking corrector, targeting poly(ADP-ribose) polymerase (PARP) |
|
DCC3030 |
Latrunculin A
Disruptor of microfilament-mediated processes |
76343-93-6 |